-
公开(公告)号：US20070160576A1
公开(公告)日：2007-07-12
申请号：US11606192
申请日：2006-11-29
申请人： David Arnott , Mercedesz Balazs , Nico Ghilardi , Austin Gurney , Philip Hass , Sarah Hymowitz , James Lee , Wenjun Ouyang , Melissa Starovasnik , Yan Wu
发明人： David Arnott , Mercedesz Balazs , Nico Ghilardi , Austin Gurney , Philip Hass , Sarah Hymowitz , James Lee , Wenjun Ouyang , Melissa Starovasnik , Yan Wu
CPC分类号： C07K16/244 , A61K38/2073 , A61K2039/505 , C07K14/54 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C07K2319/40 , G01N2500/10 , G01N2800/24 , Y02A50/463
摘要： The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
摘要翻译： 本发明涉及一种新型天然存在的人类细胞因子，其由本文称为白细胞介素17A / F（IL-17A / F）的白细胞介素-17和白细胞介素-17F的异源二聚体组成。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明多肽的嵌合多肽分子，与本发明的多肽结合的特异性抗体和用于产生 本发明。 本文还提供了治疗退行性软骨疾病和其它炎性疾病的方法。
-
公开(公告)号：US20060270003A1
公开(公告)日：2006-11-30
申请号：US10860824
申请日：2004-06-02
申请人： David Arnott , Austin Gurney , Philip Hass , James Lee , Yan Wu
发明人： David Arnott , Austin Gurney , Philip Hass , James Lee , Yan Wu
CPC分类号： C07K16/244 , A61K38/00 , C07K14/54 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/76 , G01N33/6869 , Y02A50/463 , Y02A50/473
摘要： The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
摘要翻译： 本发明涉及一种新型天然存在的人类细胞因子，其由本文称为白细胞介素17A / F（IL-17A / F）的白细胞介素-17和白细胞介素-17F的异源二聚体组成。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明多肽的嵌合多肽分子，与本发明的多肽结合的特异性抗体以及用于制备 本发明。 本文还提供了治疗退行性软骨疾病和其它炎性疾病的方法。
-
公开(公告)号：US20100291694A1
公开(公告)日：2010-11-18
申请号：US12637705
申请日：2009-12-14
申请人： Philip Hass , Jianping Yin , Kenneth Katschke , Micah Steffek , Menno Van Lookeren Campagne , Christian Wiesmann
发明人： Philip Hass , Jianping Yin , Kenneth Katschke , Micah Steffek , Menno Van Lookeren Campagne , Christian Wiesmann
IPC分类号： G01N33/68
CPC分类号： C07K14/745 , C07K2299/00
摘要： The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
摘要翻译： 本发明涉及确定巨噬细胞特异性受体CRIg（较早称为STIgMA）的晶体结构及其与补体C3（C3b：CRIg和C3c：CRIg复合物）的C3b和C3c亚基的复合物。 本发明还涉及使用CRIg或C3b：CRIg复合物的晶体结构筛选和鉴定与CRIg（包括CRIg激动剂和拮抗剂）结构和/或功能相关的分子。
-
公开(公告)号：US07776573B2
公开(公告)日：2010-08-17
申请号：US11809353
申请日：2007-05-30
申请人： Philip Hass , Jianping Yin , Kenneth Katschke , Micah Steffek , Menno Van Lookeren Campagne , Christian Wiesmann
发明人： Philip Hass , Jianping Yin , Kenneth Katschke , Micah Steffek , Menno Van Lookeren Campagne , Christian Wiesmann
CPC分类号： C07K14/745 , C07K2299/00
摘要： The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
摘要翻译： 本发明涉及确定巨噬细胞特异性受体CRIg（较早称为STIgMA）的晶体结构及其与补体C3（C3b：CRIg和C3c：CRIg复合物）的C3b和C3c亚基的复合物。 本发明还涉及使用CRIg或C3b：CRIg复合物的晶体结构筛选和鉴定与CRIg（包括CRIg激动剂和拮抗剂）结构和/或功能相关的分子。
-
公开(公告)号：US20130052685A1
公开(公告)日：2013-02-28
申请号：US13554787
申请日：2012-07-20
申请人： Philip Hass , Yin Jianping , Kenneth Katschke, JR. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
发明人： Philip Hass , Yin Jianping , Kenneth Katschke, JR. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
CPC分类号： C07K16/40 , A61K9/0048 , A61K39/3955 , A61K2039/505 , C07K2317/20 , C07K2317/24 , C07K2317/56 , C07K2317/565 , Y10S435/975
摘要： The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
-
公开(公告)号：US20110282034A1
公开(公告)日：2011-11-17
申请号：US13189301
申请日：2011-07-22
申请人： Philip Hass , Yin Jianping , Kenneth Katschke, JR. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
发明人： Philip Hass , Yin Jianping , Kenneth Katschke, JR. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
IPC分类号： C07K16/18
CPC分类号： C07K16/40 , A61K9/0048 , A61K39/3955 , A61K2039/505 , C07K2317/20 , C07K2317/24 , C07K2317/56 , C07K2317/565 , Y10S435/975
摘要： The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
摘要翻译： 本发明涉及通过施用因子D拮抗剂来预防和治疗补体相关的眼睛状况，例如脉络膜新生血管形成（CNV）和年龄相关性黄斑变性（AMD）。
-
公开(公告)号：US20090181017A1
公开(公告)日：2009-07-16
申请号：US12154466
申请日：2008-05-22
申请人： Philip Hass , Yin Jianping , Kenneth Katschke, JR. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
发明人： Philip Hass , Yin Jianping , Kenneth Katschke, JR. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
IPC分类号： A61K39/395 , A61K38/02 , A61P27/02
CPC分类号： C07K16/40 , A61K9/0048 , A61K39/3955 , A61K2039/505 , C07K2317/20 , C07K2317/24 , C07K2317/56 , C07K2317/565 , Y10S435/975
摘要： The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
摘要翻译： 本发明涉及通过施用因子D拮抗剂来预防和治疗补体相关的眼睛状况，例如脉络膜新生血管形成（CNV）和年龄相关性黄斑变性（AMD）。
-
公开(公告)号：US07930109B2
公开(公告)日：2011-04-19
申请号：US12637705
申请日：2009-12-14
申请人： Philip Hass , Jianping Yin , Kenneth Katschke , Micah Steffek , Menno Van Lookeren Campagne , Christian Wiesmann
发明人： Philip Hass , Jianping Yin , Kenneth Katschke , Micah Steffek , Menno Van Lookeren Campagne , Christian Wiesmann
CPC分类号： C07K14/745 , C07K2299/00
摘要： The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.
摘要翻译： 本发明涉及确定巨噬细胞特异性受体CRIg（较早称为STIgMA）的晶体结构及其与补体C3（C3b：CRIg和C3c：CRIg复合物）的C3b和C3c亚基的复合物。 本发明还涉及使用CRIg或C3b：CRIg复合物的晶体结构筛选和鉴定与CRIg（包括CRIg激动剂和拮抗剂）结构和/或功能相关的分子。
-
公开(公告)号：US08497094B2
公开(公告)日：2013-07-30
申请号：US13554787
申请日：2012-07-20
申请人： Philip Hass , Yin Jianping , Kenneth Katschke, Jr. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
发明人： Philip Hass , Yin Jianping , Kenneth Katschke, Jr. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
CPC分类号： C07K16/40 , A61K9/0048 , A61K39/3955 , A61K2039/505 , C07K2317/20 , C07K2317/24 , C07K2317/56 , C07K2317/565 , Y10S435/975
摘要： The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
-
公开(公告)号：US08268310B2
公开(公告)日：2012-09-18
申请号：US13189301
申请日：2011-07-22
申请人： Philip Hass , Yin Jianping , Kenneth Katschke, Jr. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
发明人： Philip Hass , Yin Jianping , Kenneth Katschke, Jr. , Micah Steffek , Christian Wiesmann , Menno Van Lookeren Campagne
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K9/0048 , A61K39/3955 , A61K2039/505 , C07K2317/20 , C07K2317/24 , C07K2317/56 , C07K2317/565 , Y10S435/975
摘要： The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
摘要翻译： 本发明涉及通过施用因子D拮抗剂来预防和治疗补体相关的眼睛状况，例如脉络膜新生血管形成（CNV）和年龄相关性黄斑变性（AMD）。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.053 秒)
